Ascletis Pharma Inc.

科学研究

Metabolic Diseases.png

Boyle, JG, et al., Clinical Science (2018) 132 1699–1709

图片1.png

学术发表

标题	发表场所	类型	时间
GLP-1R/GIPR Peptide Agonist ASC31 + ASC47 Shows 119.6% More Weight Loss than Tirzepatide in DIO Mice	2025年肥胖周（ObesityWeek® 2025）	海报	11/2025
A full analysis of 28-Day MAD Study of Oral GLP-1R Biased Small Molecule Agonist ASC30 for obesity	2025年肥胖周（ObesityWeek® 2025）	海报	11/2025
ASC30, a Once-Monthly SQ Injected Small Molecule GLP-1RA in Participants with Obesity:A Ph Ib Study	2025年肥胖周（ObesityWeek® 2025）	海报	11/2025
ASC30, an Oral GLP-1R Biased Small Molecule Agonist Demonstrated Superior Weigh Loss in Participants with Obesity: A 28-Day Multiple Ascending Dose Study	第61届欧洲糖尿病研究协会（EASD 2025）	简短口头报告	9/2025
ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model	美国糖尿病协会第85届科学会议（ADA 2025）	海报	6/2025
ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study	美国糖尿病协会第85届科学会议（ADA 2025）	海报	6/2025
ASC47, a Muscle-Preserving Weight Loss Drug Candidate in Healthy Participants: A First-in-human Single Ascending Dose Study	第32届欧洲肥胖症大会（ECO 2025）	引导型海报	5/2025
ASC47, An Adipose-Targeted, Muscle-Preserving Weight Loss Drug Candidate For Obesity, Demonstrated Significant Weight Loss And Preserved Muscle In DIO Mice	第32届欧洲肥胖症大会（ECO 2025）	口头报告	5/2025

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1